title: [Conservative therapy of patients with stable coronary heart disease].
abstract: The main treatment goals of conservative treatment of patients with stable coronary heart disease are prevention of symptoms, prevention of myocardial infarction, and heart failure and reduction of mortality. Lifestyle changes (smoking cessation, physical activity) are essential to reduce risk factors. For symptomatic treatment and prevention of angina pectoris, beta-blockers, calcium channel blockers, nitrates, I((f)) (funny channel) blockers and ranolazine are effective. Cornerstones of pharmacological prevention are drugs with prognostic effects, specifically aspirin and statins, as well as treatment of co-existing disorders such as hypertension and diabetes.
authors.affiliation: Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Deutschland. Florian.Custodis@uniklinikum-saarland.de
authors.forename: F
authors.initials: F
authors.lastname: Custodis
authors.forename: U
authors.initials: U
authors.lastname: Laufs
mesh_terms: D000083:Acetanilides / Q000009:adverse effects / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000787:Angina Pectoris / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000175:diagnosis / Q000534:rehabilitation*; D004344:Drug Incompatibility; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006333:Heart Failure / Q000175:diagnosis / Q000517:prevention & control; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008019:Life Style; D009203:Myocardial Infarction / Q000175:diagnosis / Q000517:prevention & control; D009204:Myocardial Revascularization; D009566:Nitrates / Q000009:adverse effects / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D000069458:Ranolazine; D016896:Treatment Outcome
chemical_list: D000083:Acetanilides; D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D009566:Nitrates; D010879:Piperazines; D000069458:Ranolazine